🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: FF, 50 mcg

Found 20 matching trials

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

PHASE2

This is a randomized, placebo-controlled, 2-period crossover, escalating re...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-02-09

Trial ID

NCT02991859

Treatments Being Tested

Fluticasone furoate (FF) Dry Powder Inhaler Fluticasone propionate (FP) Dry Powder Inhaler Budesonide (BUD) Turbuhaler Placebo (ELLIPTA or DISKUS)

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

PHASE2

The purpose of the study is to determine the appropriate dose of fluticason...

Status

Completed

Location

Research Site

Start Date

2006-11

Trial ID

NCT00403286

Treatments Being Tested

Fluticasone Propionate/Formoterol Fumarate Fluticasone Propionate/Formoterol Fumarate Fluticasone Propionate/Formoterol Fumarate Fluticasone Propionate/Formoterol Fumarate Fluticasone Propionate Formoterol Fumarate Fluticasone Propionate/Salmeterol Xinafoate Placebo

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

Relovair PD PK in Chinese Healthy Subjects

PHASE1

In this study, fluticasone furoate (FF) and vilanterol (VI) in different do...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-12-05

Trial ID

NCT01711463

Treatments Being Tested

Fluticasone Furoate/Vilanterol Placebo

A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)

PHASE1

The purpose of this study is to demonstrate dose proportionality of the FF ...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-08-15

Trial ID

NCT01669070

Treatments Being Tested

FF, 50 mcg FF, 100 mcg FF, 200 mcg FF, 250 mcg

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

PHASE4

There is a regulatory requirement to evaluate the extent of reduction (if a...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-07-10

Trial ID

NCT02889809

Treatments Being Tested

Fluticasone furoate Placebo Montelukast Short Acting Beta 2 Agonist

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

PHASE3

The goal of asthma treatment is to achieve and maintain asthma control and ...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-10-20

Trial ID

NCT03248128

Treatments Being Tested

FF/VI via ELLIPTA DPI FF via ELLIPTA DPI

A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine

PHASE1

This is an open label, randomized, 3-way cross-over, and repeat administrat...

Status

Completed

Location

GSK Investigational Site

Start Date

2013-10-11

Trial ID

NCT01962467

Treatments Being Tested

FF/LEV FDC FF LEV

Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma

PHASE3

Inhaled corticosteroids (ICS) have a number of known class effects includin...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-10-09

Trial ID

NCT02483975

Treatments Being Tested

FF Placebo Montelukast Albuterol/Salbutamol

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The purpose of this study is to evaluate the 24-hour spirometry effect (FEV...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-18

Trial ID

NCT01323621

Treatments Being Tested

Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg Fluticasone Propionate 250mcg / salmeterol 50mcg Double-dummy placebo Salbutamol as needed

Previous Next